Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institution
Adjuvant trastuzumab is currently an internationally standard for the treatment of localised breast cancer that over express HER2 with the most adverse effect being cardiotoxicity. We conducted this study to evaluate the cardiac safety of trastuzumab in clinical practice.
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2016-06-01
|
| Series: | Forum of Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/fco-2016-0007 |